MDS Receives U.S. Federal Trade Commission Provisional Regulatory Approval for Sale of MDS Analytical Technologies
Approval a Significant Milestone Toward Close of Transaction
All other requisite regulatory approvals required for the completion of the acquisition have now been received.
The sale of MDS Analytical Technologies to Danaher, which was announced on
MDS Inc. (TSX: MDS; NYSE: MDZ) is a global life sciences company that provides market-leading products and services that customers need for the development of drugs and the diagnosis and treatment of disease. MDS Inc. is a leading global provider of innovative technologies for use in medical imaging and radiotherapeutics, sterilization, pharmaceutical contract research, and analytical instruments. MDS has more than 3,500 highly skilled people in 13 countries. Find out more at www.mdsinc.com or by calling 1-888-MDS-7222, 24 hours a day.For further information: MEDIA: Janet Ko, (905) 267-4226, email@example.com; INVESTORS: Catherine Love, (905) 267-4230, firstname.lastname@example.org